1 / 167

Co-Occurring Substance Use and Psychiatric Disorders in Children and Adolescents

Co-Occurring Substance Use and Psychiatric Disorders in Children and Adolescents . UCLA. An Introduction to Co-Occurring Disorders. Daniel Dickerson, DO, MPH Assistant Research Psychiatrist UCLA Integrated Substance Abuse Programs Larissa Mooney, MD Associate Physician

blake
Télécharger la présentation

Co-Occurring Substance Use and Psychiatric Disorders in Children and Adolescents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Co-Occurring Substance Use and Psychiatric Disorders in Children and Adolescents UCLA

  2. An Introduction to Co-Occurring Disorders Daniel Dickerson, DO, MPH Assistant Research Psychiatrist UCLA Integrated Substance Abuse Programs Larissa Mooney, MD Associate Physician UCLA Integrated Substance Abuse Programs

  3. Objectives • Introduction of workshop context and goals • Adolescent drug abuse trends • Epidemiology of co-occurring substance use and psychiatric disorders (COD) in youth • Clinical implications of COD • Diagnostic and treatment issues

  4. Mental Health Services Act (MHSA) and COD • Mental Health Oversight and Accountability Commission (MHOAC) created in 2004. • MHOAC to provide oversight, accountability, and leadership on issues related to the Mental Health Services Act (MHSA). • MHSA passed by California voters in 2004 as Proposition 63. • Goal of MHSA to integrate COD treatment. • Each county in California, including L.A. County, provided proposition 63 funds to train psychiatrists in COD.

  5. COD recognized as an important disease entity • COD: definition: “Individuals who have at least one mental disorder as well as an alcohol or drug use disorder.” (SAMHSA, 2002) • Since 1990’s, recognition of COD in psychiatric practice has been steadily increasing • The President’s New Freedom Commission Goals and Recommendations (2004) include: “Screen for co-occurring mental and substance use disorders and link with integrated treatment strategies.” • SAMHSA’s National Advisory Council Subcommittee on COD reported to Congress on prevention and treatment on COD (SAMHSA, 2002)

  6. Adolescent Drug Abuse Trends • Approximately half of high school graduates have tried an illicit drug; 30% by 8th grade • Monitoring the Future Survey ’07: gradual decline in past-year overall illicit drug use • Past-year modest decline in use of marijuana and amphetamines • No significant change in use of cocaine, hallucinogens, heroin, prescription opioids, or cough medicines • Past-year downward trend in EtOH and tobacco use • Increase in ecstasy (MDMA) use

  7. Drug abuse Trends – continued

  8. Why do adolescents use drugs? • Gain social acceptance • Elevate mood • Alleviate anxiety • Improve self-esteem • Manage weight (stimulants) • Aphrodisiac effects • Analgesic effects (opioids)

  9. Substance Abuse: DSM-IV • A. Maladaptive pattern of use causing impairment or distress • One or more within 12-month period: • Recurrent use causing failure to fulfill role obligation (work, school, home) • Recurrent use in physically hazardous situations • Recurrent legal problems • Use despite social or interpersonal problems • B. Have never met criteria for substance dependence

  10. Substance Dependence: DSM-IV • Maladaptive pattern of use causing impairment or distress • 3 or more of following within 12-month period: • Tolerance • Withdrawal • Use in larger amounts over longer period than intended • Ongoing desire or unsuccessful efforts to cut down or control use • Excessive time spent obtaining, using, or recovering from effects • Use despite physical or psychological problem

  11. Risk Factors for SUD • Genetic (family hx SUD) • Social • Family (attitudes, experiences, divorce) • Parental (disciplinary skills, guidance, and nurturing) • Peers (attitudes, use patterns) • School (failure/dropout) • Drug availability • Age of onset of use (Bates and Labouvie, 1997) • Psychological • Psychiatric co-morbidity (Buckstein et al., 1989) • Temperament (impulsivity, negative affectivity, sensation seeking, aggression) (Bates and Labouvie, 1997) • History of physical, sexual or emotional abuse • Stressful life events • (Kaminer and Tarter, 2004)

  12. Adolescents with Substance Use Disorders... • Are largely undiagnosed • Are distributed across diverse health and social service systems • Are more likely to be involved in the juvenile justice system • Are more likely to have been victims of child abuse • Have high co-morbidity with psychiatric conditions

  13. Early Alcohol Exposure • Rate of Fetal Alcohol Syndrome (FAS) and Alcohol-Related Neurodevelopmental Disorders (ARND) combined: approximately 1 in 100 live births. (Sampson et al., 1997) • Individuals with FAS may be at higher risk for mental illness, alcohol and other drug abuse, impulsivity, and history of trauma or abuse (Baldwin, 2007) • Rodents exposed to alcohol in utero are more drawn to alcohol, suggesting teens exposed to alcohol in utero may be more likely to abuse alcohol (Youngentob et al., 2000) • Maternal drinking during pregnancy had a significant positive effect on adolescent daughters' current drinking, but a slight negative effect on sons’ lifetime drinking (Griesler and Kandel, 1998)

  14. PHYSIOLOGICAL HISTORICAL - genetics- circadian rhythms- disease states- gender - previous history- expectation- learning DRUGS ENVIRONMENTAL - social interactions- stress- conditioned stimuli BRAIN MECHANISMS BEHAVIOR ENVIRONMENT

  15. Alcohol Use and Youth • 75% of teens have used alcohol before graduating high school; 40% by 8th grade (MTF, 2005) • 40% of children who start drinking prior to age 15 will develop alcohol dependence (Grant and Dawson, 1998) • Heavy binge drinking by adolescents and young adults associated with increased long-term risk for heart disease, high blood pressure, type 2 diabetes, and other metabolic disorders (Russell et al., in press) • Withdrawal risks include seizures, delirium tremens • Adolescents may be more susceptible to memory loss than adults (Lubman et al., 2007b) • Heavier use associated with psychiatric disorders • May cause or exacerbate depressive and anxiety symptoms (Oligati et al., 2007)

  16. Marijuana Use and Youth • Among adolescents, marijuana (MJ) use is #1 illicit drug, second only to alcohol use. • Since 2001, annual prevalence of MJ use declined by 33% among 8th-graders, 25% among 10th-graders, and 14% among 12th-graders. 10% past-year use 8th grade. • 60% of youth who use drugs use only MJ • 2/3 new MJ users per year are between ages 12 and 17 • Cannabis dependence associated with mood and anxiety disorders (Dorard et al., 2008) (NHSDA, 2000; MTF, 2001 and 2007)

  17. Stimulant Use and Youth • Methamphetamine more potent than amphetamine or cocaine • Medical consequences include: tachycardia, elevated blood pressure, hyperthermia, arrhythmias, acute myocardial infarction, stroke, infectious disease risk • Psychiatric consequences include: confusion, anxiety, depression, psychosis (paranoia, hallucinations) (NIDA Research Report Series, 2004 and 2006)

  18. Inhalant Use and Youth • Inhalants (including volatile solvents, aerosols and gases) are among first drugs tried by children • About 3.0% of U.S. children have tried inhalants by 4th grade • Prevalence of abuse peaks between 7th and 9th grades • Rapid CNS effects include: euphoria, dizziness, slurred speech, incoordination; users may experience delusions and hallucinations • Medical consequences include: arrhythmias, loss of consciousness, possible death (“sudden sniffing death”) NIDA Research Report Series, 2005

  19. Prescription Drug Abuse and Youth • 15.4% high school seniors reported nonmedical use of at least one prescription drug in past year (Monitoring the Future, 2007) • 2003 NSDUH: 4% of youth ages 12-17 and 6% of 18-25 year olds reported nonmedical use of prescription medications in the past month. • 12-13 year olds reported higher rates of prescription drug use than marijuana • Between ages 12-17, females more likely to abuse prescription drugs than males (NIDA Research Report, 2005: Prescription Drug Abuse)

  20. Club Drugs and Hallucinogens • LSD • Altered sensory perception, mood swings, hallucinations, delusions, “flashbacks” • Ecstasy (MDMA) • Stimulant and hallucinogenic effects: restlessness, insomnia, altered sensory perception • Medical risks: tachycardia, hyperthermia, hyponatremia, and seizure • May cause neurotoxicity • Ketamine and PCP • Dissociative anesthetics • NIDA Research Report Series, 2001 and 2005

  21. Dextromethorphan (Coricidin HBP®) Use and Youth • Cough medicine abuse among adolescents has been increasing • Coricidin HBP® Cough and Cold is an over-the-counter cough suppressant containing a high amount of dextromethorphan • Is easily attainable (in stores) and is often stolen in large amounts • Psychiatric consequences include: transient substance-induced psychosis, potential for depression and suicidal behavior (Dickerson et al., 2008) • Medical consequences include cardiac toxicity and liver failure (Dickerson et al., 2008)

  22. Epidemiology of COD • Epidemiological studies consistently report high rates of co-morbid mental health problems among adolescents with substance use disorders (SUD). (Armstrong and Costello, 2002; Kandel et al., 1999; Rhode et al., 1996) • In a large community sample of adolescents in the United States, more than 80% of those with an alcohol use disorder had some form of lifetime psychopathology, with almost half (48%) reporting a history of depression. (Rhode et al., 1996) • In the Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) study, 32% of adolescents with a current SUD had a co-occurring mood disorder. (Kandel et al., 1999) • Utilizing data from the US National Co-morbidity Survey, co-occurrence of SUD with mental health disorders was highest among those aged 15–24 years. (Kessler et al., 1996)

  23. Psychiatric/SUD Co-morbidity • Limited studies to date on psychiatric d/o prevalence rates in youth with SUD • Alcohol, tobacco, and illicit drug use frequency associated with development of psychiatric d/o, especially conduct d/o (Kandel DB et al., 1999) • Onset of psychiatric d/o more often precedes SUD, especially conduct and anxiety d/o (Burke JD et al, 1994; Kessler RC et al., 1996) • Increased risk of suicide attempts in adolescents with co-occurring SUD and mood d/o (Kelly et al., 2004)

  24. Co-morbidity – MECA Study Kandel, DB et al., 1999

  25. Age of First Use of Primary Substance Younger than 12 for Admissions Aged 13-17, by Psychiatric Diagnosis Status: 2003 (SAMHSA, 2003)

  26. Primary Source of Referral of Adolescent Admissions, by Psychiatric Diagnosis Status: 2003 (SAMHSA, 2003)

  27. Race/Ethnicity of Adolescent Admissions, by Psychiatric Diagnosis Status: 2003 (SAMHSA, 2003)

  28. Completion of Highest Grade at Least 1 Year Behind Appropriate Age/Grade Level for Adolescent Admissions Psychiatric Diagnosis Status: 2003 Completion rates at least 1 year behind (SAMHSA, 2005)

  29. Mood and Anxiety d/o and SUD • Baseline depressive symptoms predict poor substance use outcome following adolescent residential treatment. (Subramaniam et al., 2007) • Depressive disorders frequently precede SUD in adolescents.(Bukstein et al., 1992) • Order of onset of anxiety disorders and SUD more variable: social phobia typically precedes SUD, panic d/o and GAD usually follow SUD.(Kushner et al., 1990) • Any use of cannabis at baseline predicted a modest increase in the risk of first major depression (odds ratio 1.62; 95% confidence interval 1.06-2.48) and bipolar disorder (odds ratio 4.98; 95% confidence interval 1.80-13.81). (van Laar et al., 2007)

  30. Adolescent PTSD and SUDs • Higher prevalence of PTSD in adolescents with SUD (Clark et al., 1995) • Individuals with PTSD were more likely to have: • a higher number of co-morbid mental health and substance use disorders • used more drugs in their lifetime • to report higher scores on the CESD • lower scores on the QOL-SF, including the psychological and environmental subscales. (Lubman et al., 2007)

  31. Adolescent Psychosis and SUD • Abuse of alcohol and illicit substances is common among people with psychotic illnesses (Barnett et al., 2007) • Recent emphasis on the possible links between cannabis and psychosis (Arseneault et al., 2004; Fergusson et al., 2006). • A high prevalence of cannabis use among patients with established psychotic disorders has been observed (Green et al., 2005; Barnett et al., 2007). • Dextromethorphan/Coricidin HBP abuse may be associated with transient, undiagnosed substance-induced psychosis (Dickerson et al., 2008)

  32. Adolescent ADHD and SUDs • Increasing concern regarding the likelihood of developing a SUD among teenagers with ADHD • ADHD alone and in combination with co-occurring psychopathology may be a risk factor for the development of SUDs in adulthood. • Pharmacotherapeutic treatment of ADHD in children reduces the risk for later cigarette smoking and SUDs in adulthood (Wilens & Fusillo, 2007) • However, one study reports diminished probability of developing a SUD among teenagers with ADHD when co-occurring Conduct Disorder is considered (Elkins, 2007) • Stimulant diversion continues to be of concern, particularly in older adolescents and young adults

  33. COD Diagnosis in Adolescents • “Potential problems with the diagnostic process increase almost exponentially when substance use disorders and psychiatric disorders occur together.” (Schukit, 2006) • Perform comprehensive psych evaluation including SUD screening • Obtain info from multiple sources • Have a high index of suspicion for SUD co-morbidity when patient not responding to tx

  34. COD Treatment Issues • Individualize and integrate treatment for CODs whenever possible • Consider developmental needs and stages • Consider random drug testing • Consider need for higher level of care • Consult addiction medicine specialist if necessary

  35. Treating COD within a family context • Facilitating familial involvement is key • parental collaboration • family groups • rapport building with family is important • Parent education groups are effective • orient parents to the treatment process • educate parents about addiction • encourage social support among parents and Al-Anon (Bohs, 2007)

  36. Treating COD in an ethnically-diverse population • Los Angeles is one of the most ethnically diverse regions in the U.S. • Differences in cultural beliefs and attitudes may significantly influence how psychiatric and substance use disorders manifest. • Demonstrate an interest in understanding your patient’s ethnic and cultural belief system • Achieving cultural competency is a life-long endeavor

  37. Co-Occurring Disorders,Adolescent Substance Abuse, and Psychiatric IllnessAssessment Guidelines Eraka Bath, MDDirector, Child Forensic Services Assistant Professor of Psychiatry UCLA/NPI Division of Child and Adolescent Psychiatry

  38. SUD EpidemiologyClinical Implications • Assessment and diagnosis is critical • SUD co-occurs frequently with most classes of the major psychiatric disorders • Failure to diagnose means failure to treat and confers greater morbidity from psychiatric illness • Greater morbidity confers lifelong ramifications on educational attainment, employment, service utilization, teen parenting

  39. AssessmentGeneral Guidelines • Assessing the stage of substance involvement • More appropriate method for youth in terms of development and use pattern • Adolescents tend to begin with experimentation but use can be progressive • Using stage based assessment • helps determine the severity of use • assists in specific treatment planning with regards to level of care,etc.

  40. AssessmentGeneral Guidelines • All adolescents presenting with mental health problems should be screened for substance abuse • Any change in behavior, mood, or cognitive functioning may signal SUD is major or contributing factor • Multiple Domains need to be assessed • Think of the biopsychosocial framework as a roadmap for assessment

  41. AssessmentGeneral Guidelines • Severity of Use • Consequences for the adolescent • Patterns of Use • Age of onset • Amount • Frequency • Types of agents • Negative Consequences • How obtained

  42. AssessmentGeneral Guidelines • Defining times • Places of use • Peer use • Antecedents • Consequences • Failures to control use for each type • Because teens may minimize and under-report use collaterals from family, school, peers, legal authorities and review of past treatment records is essential

  43. Warning Signs • Behavioral Changes • Disinhibition • Lethargy • Hyperactivity • Somnolence • Hyper-vigilance • Mood Changes • Depression • Euphoria • Apathy • Nervousness • Lability • Irritability • Cognitive Changes • Impaired Concentration • Changes in Attention • Perceptual Disturbance • New onset problems in psychosocial and academic functioning • Family Conflict • School Failure • Interpersonal Conflict

  44. American Academy of Child and Adolescent Psychiatry (AACAP) 2005Practice Parameters • Screening • MH Assessment of children > 9 yrs requires screening questions about ETOH and other substances [MS] • Asking about the quantity and frequency • Presence of adverse consequences of use • Adolescent's attitude toward use

  45. AACAP 2005 Practice Parameters • Evaluation • If screening raises concerns about substance use, the clinician should conduct a more formal evaluation [MS] • Toxicology should be a routine part of the formal evaluation and ongoing assessment of substance abuse both during and after treatment [MS] AACAP Practice Parameters 2005

  46. AACAP 2005 Practice Parameters • Co-morbidity • Adolescents with SUD should receive thorough evaluations for co-morbid psychiatric disorders [MS] • Co-morbid Conditions should be appropriately treated [MS] • Co-morbidity may affect an individuals ability to effectively engage in treatment (Riggs and Whitmore, 1999) • Co-morbidity (esp. depression) increases rate and rapidity of relapse (Cornelius et al. 2003)

  47. SUD and Co-morbid Psychiatric d/o – Implications for Assessment • Co-morbidity is the rule • Presence of a psychiatric disorder should be a red flag for triaging for SUD • More so with certain disorders, such as BPD, CD • Presence of a SUD should prompt triage for mental health issues

  48. SUD and Co-morbid Psychiatric d/o – Implications for Assessment • Be prepared to allocate a significant amount of time to interview to probe for substance use • Asking only one question is grossly insufficient • Don’t ignore level of functioning and functioning should be explored in multiple domains across multiple spheres

  49. Stages of UseSTAGE I • Experimental or Social Stage • Beginning stage of use • Curiosity • Following the crowd • Thrill of doing something off limits • Use helps gain acceptance of peers • Increased use can lead to Stage II Chatlos, 1996; MacDonald, 1984; Nowinski, 1990; Jaffe and Solhkhah, 2006

  50. Stages of UseSTAGE II • Substance Misuse • Actively seeking pleasurable experiences • Often learns that misuse helps facilitate escape • Use is primarily on the weekends • Usually some deterioration of grades and problems confirming with rules are noted • Increased use can led to Stage III

More Related